Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Aventis Gains FDA Approval for Apidra

By Pharmaceutical Processing | April 20, 2004

BRIDGEWATER, NJ (April 19, 2004) – The U.S. Food & Drug Administration has approved Apidra, a rapid-acting insulin analogue, for adult patients, Aventis announced. Apidra is a recombinant DNA human insulin analogue that, according to Aventis, has a more rapid onset and a shorter duration of action than regular human insulin after subcutaneous administration.

Frank L. Douglas, executive vice president for drug innovation & approval at Aventis, termed Apidra “a strong addition to the Aventis portfolio of diabetes treatments,” saying that it is similar in action to the insulin made by the body.

Apidra is designed for the treatment of type 1 and type 2 diabetes, to cover mealtime blood sugar spikes, the company said.

Diabetes is a chronic, widespread condition in which the body does not produce, or properly use insulin, the hormone needed to convert glucose (sugar) into energy. People with diabetes may need different types of insulin at certain times of the day and at different stages of the progression oftheir diabetes to help them manage their blood glucose levels.

Rapid-acting insulins can be taken shortly before or after a meal to control the peaks inblood glucose levels that happen immediately after eating, according to Aventis.

In the U.S., more than 18 million people have diabetes, including an estimated 5 million who remain undiagnosed.

Apidra was submitted for registration in the European Union and the U.S.in June 2003. It has been studied in clinical trials in adult patients with type 1and type 2 diabetes, Aventis said. It is designed to be injected within 15 minutes before ameal or within 20 minutes after starting a meal. It is intended to be givenby subcutaneous injection, or by continuous subcutaneous pump infusion, the company said.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards